Patents by Inventor Mary K. Estes
Mary K. Estes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11920165Abstract: Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologics such as neutralizing monoclonal antibodies.Type: GrantFiled: July 8, 2022Date of Patent: March 5, 2024Assignee: Baylor College of MedicineInventors: Mary K. Estes, David Graham, Robert Legare Atmar, Sue Ellen Crawford, Khalil Ettayebi, Kosuke Murakami
-
Publication number: 20220348888Abstract: Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologics such as neutralizing monoclonal antibodies.Type: ApplicationFiled: July 8, 2022Publication date: November 3, 2022Inventors: Mary K. Estes, David Graham, Robert Legare Atmar, Sue Ellen Crawford, Khalil Ettayebi, Kosuke Murakami
-
Patent number: 11396645Abstract: Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologics such as neutralizing monoclonal antibodies.Type: GrantFiled: August 24, 2020Date of Patent: July 26, 2022Assignee: Baylor College of MedicineInventors: Mary K. Estes, David Graham, Robert Legare Atmar, Sue Ellen Crawford, Khalil Ettayebi, Kosuke Murakami
-
Patent number: 11344600Abstract: The present disclosure concerns inhibitors of Norovirus protease that are suitable for use against any genotype of Norovirus, including at least GII.4 Norovirus proteases. In particular embodiments, specific compositions are encompassed, including their use for prevention or treatment of Norovirus infection in an individual.Type: GrantFiled: October 5, 2017Date of Patent: May 31, 2022Assignee: Baylor College of MedicineInventors: B. Venkataram Prasad, Mary K. Estes, Yongcheng Song
-
Publication number: 20200385690Abstract: Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologics such as neutralizing monoclonal antibodies.Type: ApplicationFiled: August 24, 2020Publication date: December 10, 2020Inventors: Mary K. Estes, David Graham, Robert Legare Atmar, Sue Ellen Crawford, Khalil Ettayebi, Kosuke Murakami
-
Patent number: 10787646Abstract: Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologies such as neutralizing monoclonal antibodies.Type: GrantFiled: October 3, 2016Date of Patent: September 29, 2020Inventors: Mary K. Estes, David Graham, Robert Legare Atmar, Sue Ellen Crawford, Khalil Ettayebi, Kosuke Murakami
-
Publication number: 20200269230Abstract: An anaerobic chamber system to evaluate human enteric disease is described herein that can be used to test therapeutic components. In specific embodiments, the anaerobic chamber is used to determine the effect of one or more bacterial communities on ex vivo enteroid cultures. In one application, the anaerobic chamber system is used to determine the efficacy of therapeutic components in ameliorating human enteric disease using personalized medicine.Type: ApplicationFiled: October 26, 2018Publication date: August 27, 2020Inventors: Tatiana Y. Fofanova, Jennifer Auchtung, Reid Laurence Wilson, Christopher Stewart, Joseph Petrosino, Robert Allen Britton, Jane Grande-Allen, Noah F. Shroyer, Mary K. Estes
-
Publication number: 20190275101Abstract: The present disclosure concerns inhibitors of Norovirus protease that are suitable for use against any genotype of Norovirus, including at least GII.4 Norovirus proteases. In particular embodiments, specific compositions are encompassed, including their use for prevention or treatment of Norovirus infection in an individual.Type: ApplicationFiled: October 5, 2017Publication date: September 12, 2019Inventors: B. Venkataram Prasad, Mary K. Estes, Yongcheng Song
-
Publication number: 20180282704Abstract: Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologies such as neutralizing monoclonal antibodies.Type: ApplicationFiled: October 3, 2016Publication date: October 4, 2018Inventors: Mary K. Estes, David Graham, Robert Legare Atmar, Sue Ellen Crawford, Khalil Ettayebi, Kosuke Murakami
-
Patent number: 10024856Abstract: Embodiments of the disclosure include methods and/or compositions for the detection of viral infection, including at least Norovirus infection. In particular embodiments, there are methods and/or compositions employing particular peptides and/or phage useful for detecting Norovirus in a sample. The sample may be from an environment or from an individual. The individual may be a mammal, including a human, cow, horse, dog, cat, pig, and so forth. Certain exemplary peptides and phage that express the peptides are identified as useful for binding to Norovirus. Such peptides and phage are provided to one or more samples in order to identify whether or not Norovirus is present in the sample.Type: GrantFiled: March 21, 2014Date of Patent: July 17, 2018Assignee: Baylor College of MedicineInventors: Timothy Gerald Palzkill, Mary K. Estes, Robert Legare Atmar, Jennifer Dawn Rogers, Nadim Jose Ajami
-
Publication number: 20160061835Abstract: Embodiments of the disclosure include methods and/or compositions for the detection of viral infection, including at least Norovirus infection. In particular embodiments, there are methods and/or compositions employing particular peptides and/or phage useful for detecting Norovirus in a sample. The sample may be from an environment or from an individual. The individual may be a mammal, including a human, cow, horse, dog, cat, pig, and so forth. Certain exemplary peptides and phage that express the peptides are identified as useful for binding to Norovirus. Such peptides and phage are provided to one or more samples in order to identify whether or not Norovirus is present in the sample.Type: ApplicationFiled: March 21, 2014Publication date: March 3, 2016Inventors: Timothy Gerald Palzkill, Mary K. Estes, Robert Legare Atmar, Jennifer Dawn Rogers, Nadim Jose Ajami
-
Publication number: 20120021405Abstract: The present invention concerns compositions and methods for detecting Norovirus or Norovirus particles. In particular, the present invention encompasses antibodies for detecting Norovirus or Norovirus particles, including, for example, monoclonal antibodies that have broad specificity of binding to various genogroups of norovirus.Type: ApplicationFiled: January 26, 2010Publication date: January 26, 2012Applicant: Baylor College of MedicineInventors: Timothy Palzkill, Wanzhi Huang, Mary K. Estes
-
Patent number: 6942865Abstract: Double-stranded cDNA was synthesized from nucleic acid extracted from Norwalk virus purified from stool specimens of volunteers. One clone was isolated from a cDNA library constructed in a pUC-13 vector after amplification of the cDNA. The specificity of this cDNA (pUCNV-953) was shown by hybridization assays. The cDNA reacted with post (but not pre-) infection stool samples from Norwalk volunteers and with highly purified Norwalk virus, but not with other common enteric viruses such as hepatitis A virus and rotavirus. Finally, the probe detected virus in the same fractions of CsCl gradients in which viral antigen was detected using a specific Norwalk virus radioimmunoassay, and particles were detected by immune electron microscopy. Single-stranded RNA probes derived from the DNA clone after subcloning into an in vitro transcription vector were also used to show that the Norwalk virus contains a ssRNA genome of about 8 kb in size.Type: GrantFiled: December 9, 2002Date of Patent: September 13, 2005Assignee: Baylor College of MedicineInventors: Mary K. Estes, Xi Jiang, David Y. Graham
-
Patent number: 6780630Abstract: The invention relates to an improved rotavirus vaccine for man and animals and methods of using them. The invention comprises a method of immunizing humans, particularly children, and animals against rotavirus infections by parenteral immunization. The immunization may be carried out in a series of injections using live or inactivated vaccines, alone or in combination with each other or in combination with a rotavirus subunit vaccine or oral vaccine.Type: GrantFiled: July 10, 1992Date of Patent: August 24, 2004Assignee: Baylor College of MedicineInventors: Mary K. Estes, Margaret E. Conner
-
Patent number: 6673355Abstract: The rotavirus nonstructural glycoprotein, NSP4, performs multiple functions in the virus replication cycle, especially during viral morphogenesis. Specifically, NSP4 is an intracellular receptor that mediates the acquisition of a transient membrane envelope during the budding of newly formed subviral particles into the endoplasmic reticulum (ER). The present invention relates to NSP4 and methods of use. More particulary, it relates to the use of NSP4 and fragments thereof (NSP4 114-135, NSP4 120-147, NSP4 112-174, or NSP4 112-150) as a prevention and/or treatment of rotaviral disease.Type: GrantFiled: November 3, 2000Date of Patent: January 6, 2004Assignee: Baylor College of MedicineInventors: Mary K. Estes, Judith M. Ball, Peng Tian
-
Publication number: 20030129588Abstract: Double-stranded cDNA was synthesized from nucleic acid extracted from Norwalk virus purified from stool specimens of volunteers. One clone was isolated from a cDNA library constructed in a pUC-13 vector after amplification of the cDNA. The specificity of this cDNA (pUCNV-953) was shown by hybridization assays. The cDNA reacted with post (but not pre-) infection stool samples from Norwalk volunteers and with highly purified Norwalk virus, but not with other common enteric viruses such as hepatitis A virus and rotavirus. Finally, the probe detected virus in the same fractions of CsCl gradients in which viral antigen was detected using a specific Norwalk virus radioimmunoassay, and particles were detected by immune electron microscopy. Single-stranded RNA probes derived from the DNA clone after subcloning into an in vitro transcription vector were also used to show that the Norwalk virus contains a ssRNA genome of about 8 kb in size.Type: ApplicationFiled: December 9, 2002Publication date: July 10, 2003Applicant: Baylor College of MedicineInventors: Mary K. Estes, Xi Jiang, David Y. Graham
-
Publication number: 20030113788Abstract: This invention relates to a method of potentiating an immune response by administering a viral enterotoxin or derivative as an adjuvant. More particularly it relates to administering a viral enterotoxin or derivative as an adjuvant and an antigen to a mucosal surface of a mammal.Type: ApplicationFiled: December 24, 2002Publication date: June 19, 2003Applicant: Baylor College of MedicineInventor: Mary K. Estes
-
Patent number: 6572862Abstract: Recombinant proteins and peptides of Norwalk virus are claimed. Also claimed are vaccines against Norwalk virus and methods of immunizing against Norwalk virus using recombinant Norwalk virus antigens and derivatives thereof. Also claimed are vaccines for non-Norwalk virus agents including a portion of the Norwalk virus capsid as a carrier.Type: GrantFiled: June 7, 1995Date of Patent: June 3, 2003Assignee: Baylor College of MedicineInventors: Mary K. Estes, Xi Jiang, David Y. Graham
-
Patent number: 6534067Abstract: This invention relates to a method of potentiating an immune response by administering a viral enterotoxin or derivative as an adjuvant. More particularly it relates to administering a viral enterotoxin or derivative as an adjuvant and an antigen to a mucosal surface of a mammal.Type: GrantFiled: October 13, 2000Date of Patent: March 18, 2003Assignee: Baylor College of MedicineInventor: Mary K. Estes
-
Patent number: 6210682Abstract: Methods of immunization against rotavirus infection or rotavirus disease by administering to a subject a peptide NSP4 114-135, a peptide NSP4 120-147, or a toxoid thereof are disclosed.Type: GrantFiled: May 26, 1998Date of Patent: April 3, 2001Assignee: Baylor College of MedicineInventors: Mary K. Estes, Judith Ball, Peng Tien